265 related articles for article (PubMed ID: 19877992)
1. Aqueous film coating to reduce recrystallization of guaifenesin from hot-melt extruded acrylic matrices.
Bruce CD; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Drug Dev Ind Pharm; 2010 Feb; 36(2):218-26. PubMed ID: 19877992
[TBL] [Abstract][Full Text] [Related]
2. Crystal growth formation in melt extrudates.
Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
[TBL] [Abstract][Full Text] [Related]
3. The influence of heterogeneous nucleation on the surface crystallization of guaifenesin from melt extrudates containing Eudragit L10055 or Acryl-EZE.
Bruce CD; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Eur J Pharm Biopharm; 2010 May; 75(1):71-8. PubMed ID: 19995604
[TBL] [Abstract][Full Text] [Related]
4. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
Sauer D; Zheng W; Coots LB; McGinity JW
Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
[TBL] [Abstract][Full Text] [Related]
5. The manufacture and characterisation of hot-melt extruded enteric tablets.
Andrews GP; Jones DS; Diak OA; McCoy CP; Watts AB; McGinity JW
Eur J Pharm Biopharm; 2008 May; 69(1):264-73. PubMed ID: 18164604
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the film formation of the dry coating process.
Kablitz CD; Urbanetz NA
Eur J Pharm Biopharm; 2007 Sep; 67(2):449-57. PubMed ID: 17451928
[TBL] [Abstract][Full Text] [Related]
7. Sustained release coating of tablets with Eudragit(®) RS/RL using a novel electrostatic dry powder coating process.
Qiao M; Luo Y; Zhang L; Ma Y; Stephenson TS; Zhu J
Int J Pharm; 2010 Oct; 399(1-2):37-43. PubMed ID: 20678560
[TBL] [Abstract][Full Text] [Related]
8. A novel powder coating process for attaining taste masking and moisture protective films applied to tablets.
Cerea M; Zheng W; Young CR; McGinity JW
Int J Pharm; 2004 Jul; 279(1-2):127-39. PubMed ID: 15234801
[TBL] [Abstract][Full Text] [Related]
9. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
[TBL] [Abstract][Full Text] [Related]
10. Preparation and in vitro evaluation of gliclazide sustained-release matrix pellets: formulation and storage stability.
Wang L; Wang J; Lin X; Tang X
Drug Dev Ind Pharm; 2010 Jul; 36(7):814-22. PubMed ID: 20345281
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical properties of film-coated melt-extruded pellets.
Young CR; Crowley M; Dietzsch C; McGinity JW
J Microencapsul; 2007 Feb; 24(1):57-71. PubMed ID: 17438942
[TBL] [Abstract][Full Text] [Related]
12. Protection of moisture-sensitive drugs with aqueous polymer coatings: importance of coating and curing conditions.
Bley O; Siepmann J; Bodmeier R
Int J Pharm; 2009 Aug; 378(1-2):59-65. PubMed ID: 19477253
[TBL] [Abstract][Full Text] [Related]
13. Novel application of hot-melt extrusion for the preparation of monolithic matrices containing enteric-coated particles.
Schilling SU; McGinity JW
Int J Pharm; 2010 Nov; 400(1-2):24-31. PubMed ID: 20727956
[TBL] [Abstract][Full Text] [Related]
14. Stability study of ambroxol hydrochloride sustained release pellets coated with acrylic polymer.
Kibria G; Islam KM; Jalil RU
Pak J Pharm Sci; 2009 Jan; 22(1):36-43. PubMed ID: 19168418
[TBL] [Abstract][Full Text] [Related]
15. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
16. The influence of guaifenesin and ketoprofen on the properties of hot-melt extruded polyethylene oxide films.
Crowley MM; Fredersdorf A; Schroeder B; Kucera S; Prodduturi S; Repka MA; McGinity JW
Eur J Pharm Sci; 2004 Aug; 22(5):409-18. PubMed ID: 15265510
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of poly(styrene-alt-maleic anhydride)-ethanol as enteric coating material.
Lai X; Sun C; Tian H; Zhao W; Gao L
Int J Pharm; 2008 Mar; 352(1-2):66-73. PubMed ID: 18054184
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the drug release patterns and long term stability of aqueous and organic coated pellets by using blends of enteric and gastrointestinal insoluble polymers.
Kranz H; Gutsche S
Int J Pharm; 2009 Oct; 380(1-2):112-9. PubMed ID: 19632313
[TBL] [Abstract][Full Text] [Related]
19. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
Missaghi S; Young C; Fegely K; Rajabi-Siahboomi AR
Drug Dev Ind Pharm; 2010 Feb; 36(2):180-9. PubMed ID: 20070183
[TBL] [Abstract][Full Text] [Related]
20. Influence of polymeric subcoats on the drug release properties of tablets powder-coated with pre-plasticized Eudragit L 100-55.
Sauer D; Watts AB; Coots LB; Zheng WC; McGinity JW
Int J Pharm; 2009 Feb; 367(1-2):20-8. PubMed ID: 18848872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
